In support to the present findings is the study by Ye et al. [37], who found a decrease in phospho-YAP over YAP—i.e., YAP activation, in a mouse model of NASH-precarcinoma. The gene discussed is YAP1; the disease is metabolic dysfunction-associated steatohepatitis.